ペグインターフェロンアルファ-2a、ペグインターフェロンアルファ2a
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/11/22 04:39:11」(JST)
[Wiki en表示]
|
|
This article relies on references to primary sources or sources affiliated with the subject. Please add citations from reliable and independent sources. (November 2008) |
Peginterferon alfa-2a
|
| Clinical data |
| AHFS/Drugs.com |
Consumer Drug Information |
| MedlinePlus |
a605029 |
| Pregnancy cat. |
? |
| Legal status |
? |
| Routes |
subcutaneous |
| Identifiers |
| CAS number |
215647-85-1 N |
| ATC code |
L03AB11
L03AB61 (in combinations) |
| DrugBank |
DB00008 |
| UNII |
Q46947FE7K N |
| KEGG |
D02748 Y |
| ChEMBL |
CHEMBL1201560 N |
| Chemical data |
| Formula |
C860H1353N227O255S9 |
| Mol. mass |
19241 g/mol (unpegylated)
40000 g/mol (pegylated) |
N (what is this?) (verify)
|
Pegylated interferon alfa-2a (pegylated with a branched 40 kDa PEG chain; commercial name Pegasys) is an antiviral drug discovered at the pharmaceutical company F. Hoffmann-La Roche; it has a dual mode of action - both antiviral and on the immune system. The addition of polyethylene glycol to the interferon, through a process known as pegylation, enhances the half-life of the interferon when compared to its native form.
|
Contents
- 1 Uses
- 2 Host genetic factors influencing treatment response
- 3 See also
- 4 References
- 5 External links
|
Uses
This drug is approved around the world for the treatment of chronic hepatitis C (including patients with HIV co-infection, cirrhosis, 'normal' levels of ALT) and has recently been approved (in the EU, U.S., China and many other countries) for the treatment of chronic hepatitis B.
Peginterferon alfa-2a is a long acting interferon. Interferons are proteins released in the body in response to viral infections. Interferons are important for fighting viruses in the body, for regulating reproduction of cells, and for regulating the immune system.[citation needed]
Host genetic factors influencing treatment response
For genotype 1 hepatitis C treated with Pegylated interferon-alpha-2a or Pegylated interferon-alpha-2b (brand names Pegasys or PEG-Intron) combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature [1], showed genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. Later report from Nature [2] demonstrated the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus. Also for Nawab
See also
References
- ^ Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401. doi:10.1038/nature08309. PMID 19684573.
- ^ Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature 461 (7265): 798–801. doi:10.1038/nature08463. PMC 3172006. PMID 19759533. //www.ncbi.nlm.nih.gov/pmc/articles/PMC3172006/.
External links
- Interferon and hepatitis c at pegasys.com
- PMPRB at pmprb-cepmb.gc.ca
- Chemical structure at hepalife.com
- Pegasys at the US National Library of Medicine Medical Subject Headings (MeSH)
|
Cell signaling: cytokines
|
|
| By family |
|
|
By function/
cell |
|
|
|
B trdu: iter (nrpl/grfl/cytl/horl), csrc (lgic, enzr, gprc, igsr, intg, nrpr/grfr/cytr), itra (adap, gbpr, mapk), calc, lipd; path (hedp, wntp, tgfp+mapp, notp, jakp, fsap, hipp, tlrp)
|
|
|
Immunomodulators: Immunostimulants (L03)
|
|
| Endogenous |
|
Cytokines
|
|
Colony-stimulating factors
|
- G-CSF (Filgrastim/Pegfilgrastim
- Lenograstim)
- GM-CSF (Molgramostim
- Sargramostim)
- SCF (Ancestim)
|
|
|
Interferons
|
- alpha: Interferon alfa natural
- Interferon alfa-2a/Peginterferon alfa-2a
- Interferon alfa-2b/Peginterferon alfa-2b
- Interferon alfa-n1
- Interferon alpha-n3
- Interferon alfacon-1
- Albinterferon
- beta: Interferon beta natural
- Interferon beta-1a
- Interferon beta-1b
Interferon gamma
|
|
|
Interleukins
|
|
|
|
|
Other protein/peptide
|
- Pegademase
- Immunocyanin
- Tasonermin
- Prolactin
- Growth hormone
|
|
|
Other
|
- Female sex steroids
- Vitamin D
- Poly ICLC
- Histamine dihydrochloride
|
|
|
| Exogenous |
- vaccines (BCG vaccine
- Melanoma vaccine
- Sipuleucel-T)
- beta-glucan (Lentinan)
- Mifamurtide
- thiazolidine (Pidotimod)
- heterocyclic compound (Plerixafor)
- polyribonucleotide (Polyinosinic:polycytidylic acid)
- hydroxyquinoline (Roquinimex)
- oligopeptides (Glatiramer acetate
- Thymopentin
- Thymosin α1
- Thymulin)
|
|
|
|
cell/phys/auag/auab/comp, igrc
|
|
|
|
|
|
|
DNA virus antivirals (primarily J05, also S01AD and D06BB)
|
|
| Baltimore I |
|
Herpesvirus
|
|
DNA-synthesis
inhibitor
|
|
TK activated
|
|
Purine analogue
|
- guanine (Aciclovir#/Valacyclovir
- Ganciclovir/Valganciclovir
- Penciclovir/Famciclovir)
|
|
|
Pyrimidine analogue
|
- uridine (Idoxuridine
- Trifluridine
- Edoxudine)
|
|
|
|
Not TK activated
|
|
|
|
|
Other
|
- Docosanol
- early protein (Fomivirsen)
- Tromantadine
|
|
|
|
HPV/MC
|
- Imiquimod/Resiquimod
- Podophyllotoxin
|
|
|
Vaccinia
|
|
|
|
Poxviridae
|
|
|
|
| Hepatitis B (VII) |
- Nucleoside analogues/NARTIs: Entecavir
- Lamivudine
- Telbivudine
- Clevudine
- Nucleotide analogues/NtRTIs: Adefovir
- Tenofovir
|
|
| Multiple/general |
|
Nucleic acid inhibitors
|
|
|
|
Interferon
|
- Interferon alfa-2b
- Peginterferon alfa-2a
|
|
|
Multiple/unknown
|
- Ribavirin#/Taribavirin†
- Moroxydine
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
cutn/syst (hppv/hiva, infl/zost/zoon)/epon
|
drug(dnaa, rnaa, rtva, vacc)
|
|
|
|
|
RNA virus antivirals (primarily J05, also S01AD and D06BB)
|
|
| Hepatitis C |
- protease inhibitors (Boceprevir
- Telaprevir) NS5A inhibitor (ACH-3102†, Daclatasvir†)
|
|
| Picornavirus |
|
|
| Anti-influenza agents |
- adamantane derivatives/M2 inhibitors (Amantadine
- Rimantadine)
- neuraminidase inhibitors/release phase (Oseltamivir
- Zanamivir
- Peramivir†, Laninamivir†)
|
|
| Multiple/general |
|
Interferon
|
- Interferon alfa-2b
- Peginterferon alfa-2a
|
|
|
Multiple/unknown
|
- Ribavirin#/Taribavirin†
- Moroxydine
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
|
cutn/syst (hppv/hiva, infl/zost/zoon)/epon
|
drug(dnaa, rnaa, rtva, vacc)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.
- Tatum H1, Thuluvath PJ2, Lawitz E3, Martorell C4, DeMicco M5, Cohen S6, Rustgi V7, Ravendhran N8, Ghalib R9, Hanson J10, Zamparo J11, Zhao J12, Cooney E11, Treitel M13, Hughes E13.
- Journal of viral hepatitis.J Viral Hepat.2015 Aug;22(8):658-64. doi: 10.1111/jvh.12372. Epub 2014 Dec 15.
- Beclabuvir is a potent, non-nucleoside inhibitor of the HCV NS5B RNA polymerase, with nanomolar activity against HCV genotypes 1, 3, 4, 5 and 6 in vitro. This study evaluated the efficacy and safety of beclabuvir, in combination with peginterferon alfa-2a (pegIFN) and ribavirin (RBV), in HCV genotyp
- PMID 25496007
- A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update.
- Martin P1, Lau DT2, Nguyen MH3, Janssen HL4, Dieterich DT5, Peters MG6, Jacobson IM7.
- Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2015 Jul 15. pii: S1542-3565(15)00963-5. doi: 10.1016/j.cgh.2015.07.007. [Epub ahead of print]
- Chronic hepatitis B (CHB) continues to be an important public health problem worldwide, including in the United States. An algorithm for managing CHB was developed by a panel of United States hepatologists in 2004 and subsequently updated in 2006 and 2008. Since 2008, additional data on long-term sa
- PMID 26188135
- Perspectives on dual hepatitis B and C infection in Taiwan.
- Liu CJ1, Chen PJ2, Chen DS2, Tseng TC3, Kao JH2.
- Journal of the Formosan Medical Association = Taiwan yi zhi.J Formos Med Assoc.2015 Jul 15. pii: S0929-6646(15)00228-4. doi: 10.1016/j.jfma.2015.06.005. [Epub ahead of print]
- Dual hepatitis C virus (HCV) and hepatitis B virus (HBV) infection is not rare in HBV or HCV endemic areas, and can be found in populations at risk of parenteral viral transmission. Clinical observatory studies suggest a higher risk of liver disease progression in patients with dual HCV/HBV infectio
- PMID 26188762
Japanese Journal
- C型肝炎症例におけるペグインターフェロンα2a少量長期投与における肝発癌抑止効果 (特集 C型肝炎治療の新たな展開)
- B型慢性肝炎患者に対するペグインターフェロンα-2αの有効性及び安全性の検討
- 林 紀夫,清澤 研道,坪内 博仁 [他],岡上 武,熊田 博光
- 肝臓 53(3), 135-146, 2012-03-25
- … B型慢性肝炎に対するペグインターフェロンアルファ-2a（PEG-IFNα-2a）の有効性，安全性を検討した． … HBe抗原陽性例はPEG-IFNα-2a 90 μg，180 μg/週の各々24週投与，48週投与又は天然型IFNα6 MIU週3回24週投与（HLBI群）の5群に無作為割付けし，投与終了後24週時のALT正常化，HBeセロコンバージョン及びHBV-DNA量抑制の複合評価で有効性を評価した． …
- NAID 10030547248
- ペグインターフェロンα-2a・リバビリン療法を受けるC型慢性肝炎患者のQOLの推移と看護支援の検討
Related Links
- Before using peginterferon alfa-2a, tell your doctor and pharmacist if you are allergic to peginterferon alfa-2a, other alpha interferons, any other medications, benzyl alcohol, or polyethylene glycol (PEG). Ask your doctor if ...
- Side Effect Reporting You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835 ... What it Treats What is PEGASYS? PEGASYS ® (peginterferon alfa-2a) is a prescription medication that is:
Related Pictures
★リンクテーブル★
[★]
- 英
- peginterferon alfa-2a
- 関
- ペグインターフェロンアルファ2a
[★]
- 関
- alpha